Comparative Pharmacology
Head-to-head clinical analysis: DISOMER versus HISTAFED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOMER versus HISTAFED.
DISOMER vs HISTAFED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective dopamine D2 receptor antagonist; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
Adults: 1 mg orally once daily.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
None Documented
None Documented
12–15 hours in adults with normal renal function; prolonged to 30–40 hours in severe renal impairment (CrCl <30 mL/min).
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; <5% unchanged in feces.
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination